Government to pay 200 yuan per dose of Chinese COVID-19 inactivated vaccines

Source: Global Times Published: 2020/12/16 14:14:30

A staff member displays a sample of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group Co., Ltd. (Sinopharm) in Beijing, capital of China, April 10, 2020. (Xinhua/Zhang Yuwei)

Leading Chinese COVID-19 vaccine producers including Sinopharm and Sinovac will charge the government 200 yuan ($30.57) per dose, as East China's Jiangsu becomes the latest province to purchase two types of domestically developed inactivated vaccines for emergency use at this wholesale price, according to a public document posted on the official website on Tuesday.

The price is the same as the one several other provinces, such as East China's Zhejiang Province and Southwest China's Sichuan Province, previously paid for COVID-19 vaccines.

The latest document shows that two inactivated vaccines negotiated in a government contract are from two leading producers -- Sinopharm and Sinovac, but did not specify the number of doses from each manufacturer.

Southwest China's Sichuan Province has begun coronavirus vaccine emergency use for 12 types of high-risk groups -- about 2 million people -- with inoculation scheduled to be completed by the end of the year, media reported.

It was reported that inactivated COVID-19 vaccines were the main vaccines to be administered in Sichuan. The vaccine costs 200 yuan ($30.62) per dose, the same as the one used in Zhejiang Province launched in October.

In a recent online poll involving around 150 participants on Sina Weibo, more than 80 percent people believed the price is affordable and acceptable. 

US pharmaceutical firm Pfizer recently announced its wholesale price negotiated in a government contract at $20 per dose, while Moderna will charge governments between $10 and $50 per dose, media reported.

CanSino, another Chinese frontrunner vaccine producer, has not yet disclosed its vaccine price.

Posted in: SOCIETY

blog comments powered by Disqus